Artificial intelligence in precision mRNA therapeutics: Towards genomic language models and multi-agent virtual humans

Искусственный интеллект в прецизионной терапии мРНК: на пути к геномным языковым моделям и мультиагентным виртуальным людям
Tingting Tan, Yizhu Diao, Xueyao Yu, Liye Chen, Hai Fang
2026-01-01

genomic language modelslipid nanoparticle designmulti-agent virtual humansneoantigen discoveryprecision mRNA therapeutics
The success of COVID-19 vaccines has validated mRNA as a versatile therapeutic platform, whose expanding clinical spectrum covers immunotherapeutics for oncology (targeting oncogenes and tumour suppressor genes), autoimmunity, and infectious diseases, as well as non-immunotherapeutic applications. However, challenges in stability, delivery efficiency, and immunogenicity persist. This Review outlines how emerging RNA architectures—self-amplifying (saRNA), circular (circRNA), and trans-amplifying (taRNA)—address conventional mRNA limitations via structural engineering, while articulating the pivotal role of artificial intelligence (AI) in overcoming these hurdles across the entire mRNA drug development pipeline. We explore how AI is revolutionising key areas, such as multi-omics-guided neoantigen discovery, coding sequence and untranslated region optimisation, rational lipid nanoparticle design, and in vivo pharmacological prediction. Looking ahead, we highlight AI agents powered by genomic language models and multi-agent virtual humans (including our proposed PimRNAgent framework) that promise to automate iterative design-validation cycles and facilitate personalised mRNA therapeutics. Ultimately, the convergence of AI with next-generation mRNA platforms is paving the way for a new era of clinically actionable, precision-based mRNA therapeutics.
1
AI can improve the mRNA development pipeline through multi-omics-guided neoantigen discovery, sequence optimization, lipid nanoparticle design, and in vivo pharmacological prediction.
2
Genomic-language-model agents and multi-agent virtual humans, including the proposed PimRNAgent framework, could automate design-validation cycles and enable personalized mRNA therapeutics.
3
Self-amplifying, circular, and trans-amplifying RNA architectures address conventional mRNA constraints through structural engineering.
4
Stability, delivery efficiency, and immunogenicity remain central limitations of conventional mRNA therapeutics.
5
mRNA therapeutics are expanding beyond COVID-19 vaccines into oncology, autoimmunity, infectious diseases, and non-immunotherapeutic applications.

precision mRNA therapeutics and next-generation RNA platforms, including self-amplifying, circular, and trans-amplifying RNA

AI-enabled design, optimization, delivery, pharmacological prediction, and personalized development of mRNA therapeutics across the drug development pipeline

Publication Details
Publication Date
2026-01-01
Journal
Publisher
ISSN
Cited by
9
Access Type
Author Information
Authors
Tingting Tan
Yizhu Diao
Xueyao Yu
Liye Chen
Hai Fang
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%